Funded Tech Companies
AnaCardio
Wondering who provided funding to AnaCardio? Pureos Bioventures, Helsinn Investment Fund and Flerie Invest joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
AnaCardio
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
A Working Lab Innomedicum, Nanna Svartz väg 4
Solna, 171 65
Sweden
Solna, 171 65
Sweden
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
9/30/2026
Financing History
Management Team
Title
Name
Email & Social
Chairman
Lars Lund
Chief Executive Officer
Patrik Strömberg
Company Investors
- Pureos Bioventures
- Helsinn Investment Fund
- Flerie Invest
- The Ljungstrom Family Office
- Sound Bioventures
- Innovestor
- Novo Holdings
- Industrifonden
- 3B Ventures
- Karolinska
- Private Investors (Ann-Helene Ljungström)
- Private Investors (Fredrik Ljungstrom)
Browse more funded tech companies:
Share this article
About Our VC Deals Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs